[Media Report]: "Horien"
Gennu-Plug Wins Award
Horien Biochemical Technology Co., Ltd. is a large-scale high-tech company jointly
established by a US technology fund, Formosa Optical, and Ginko Group. The
company has successfully extracted pure collagen from native pig tendons, a
source with the highest biocompatibility with the human body, and successfully
developed the "Gennu-Plug" dental
wound care material. This medical device is a wound dressing specifically
designed for dental implants, orthodontics, and tooth extraction procedures. In
addition to obtaining the Class III Medical Device Certificate from the
Department of Health, Executive Yuan, it was awarded the 2010 "National
Biotechnology and Medical Quality Award" and the "SNQ National
Quality Mark" in December 2009.
Ho Hsin-Yu, Deputy CEO of Horien Biochemical, stated that Taiwanese
pig farmers have long focused on developing the market for edible meat. With
the dedicated guidance of the Ministry of Economic Affairs and the Council of
Agriculture, some pig farmers have acquired production traceability and are
highly aware of the risks associated with antibiotics and sulfonamides. They
also work closely with veterinarians for inspections, significantly increasing
the rate at which Taiwanese pigs can be used in high-end medical devices. Three
years ago, Horien also
began assisting local pig farmers in understanding EU and US regulations
regarding the use of animal-derived medical devices, allowing farmers to
broaden their horizons and explore new avenues for development.
Horien is a
subsidiary of the Ginko Group’s Biochemical
Business Group, bringing together experts in fields including medicine,
pharmacy, biomedical engineering, chemical engineering, molecular biology,
microbiology, clinical medicine, immunology, botany, and applied cosmetics.
Specializing in pharmaceutical-grade collagen biomedical composite materials
and the development of clinical and tissue engineering applications, such as
dental wound protectants and artificial conjunctiva—iGenR—the company will
accelerate its development of biodegradable scleral buckles, artificial skin,
periodontal regeneration membranes, pulp regeneration materials, dura mater
replacement materials, drug delivery devices, and tubular materials using its
core collagen technology. Ho Hsin-Yu emphasized
that the company aspires to develop an artificial cornea in the near future,
restoring sight to the blind.
Horien Biochemical Technology and its subsidiary, Shengli Biotechnology Co., Ltd.,
also have a cosmetic raw material development department. Having undergone
formal human clinical trials at China Medical University and Tri-Service
General Hospital, they have successfully developed anti-wrinkle and whitening
raw materials such as 17-peptides and 21-peptides. Three years ago, they also
successfully extracted a cosmetic-grade raw material beneficial for skin
moisturizing by artificially cultivating "Ula grass," one of the
three treasures of Northeast China, at an agricultural base in Qiqihar.
The company will be showcasing its products at the
Taipei World Trade Center Hall 1, Area D, Booth 427 (Biotechnology &
Aesthetic Medicine Zone). On July 24th at 1 PM, they will publicly unveil their
new cosmetic product, "Collagen Softening Tablets," on the main
stage. The company's R&D executives will be present to explain the product.
(Information from the Commercial Times, Taipei)
